Earnings ·
Korro Bio reported a net loss of $18.9 million for the quarter ended June 30, 2026, compared to $25.8 million in the…
KRROKorro Bio, Inc.
Korro Bio reported a net loss of $18.9 million for the quarter ended June 30, 2026, compared to $25.8 million in the prior year period. The company ended the quarter with $137.9 million in cash and marketable securities, providing a runway into the second half of 2028. Korro received Orphan Drug Designation from the European Medicines Agency for KRRO-121 to treat urea cycle disorders and nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency, with preclinical data showing over 90% editing of pathogenic transcripts. Additionally, Korro entered into an exchange agreement with VenRock Healthcare Capital Partners on August 5, 2026, whereby VenRock surrendered 1,000,000 shares for no consideration in exchange for pre-funded warrants to purchase 1,000,000 shares at $0.001 per share exercise price with no expiration date. Following the transaction, Korro had 13,725,646 common shares outstanding and unexercised pre-funded warrants for an additional 4,148,836 shares. Korro Bio is a biopharmaceutical company developing genetic medicines using its proprietary RNA editing platform.